Recalls
Searchable archive of product recalls from the FDA, USDA FSIS, CPSC, NHTSA, and EPA — translated into plain English, severity-scored from objective criteria, and always linked back to the original government notice.
Every recall on this list has been scored 1–5 against an objective rubric from the agency’s own classification, presence of reported injuries or deaths, distribution scope, and hazard type. The colored severity badge on each card is the score — 5 (Critical) means deaths or serious injuries are reported, 4 (Severe) means significant injury or hospitalization risk, and 3 (High) means a known hazard with no confirmed harm yet. Filter to 3+ (High and above) if you want to skip routine Class-III notices.
The agency chips above control which streams are visible. FDA spans food, drugs, and medical devices. USDA FSIS is meat, poultry, and processed egg products. CPSC is household consumer products. NHTSA is vehicles, tires, and child seats. Nationwide on a card means the recall affects every US state — most do — while a state list means distribution was limited.
Click any recall to see the full summary, affected lot codes and model numbers, the agency’s own classification, and a direct link back to the original government notice for verification.
Minimum severity
SCA Pharmaceuticals is recalling Lidocaine HCl 2% syringes because foreign material was found inside the vials.
Jubilant Cadista Pharmaceuticals is recalling 1,824 bottles of Amantadine Hydrochloride Tablets because a foreign object was found in a single tablet.
Anazao Health is recalling compounded Clonidine, Prialt, and Bupivacaine syringes because environmental sampling detected Talaromyces rotundus, a fungus.
Amneal Pharmaceuticals is recalling Ranitidine Tablets 150 mg because the active ingredient contained the impurity N-nitrosodimethylamine (NDMA).
Preferred Pharmaceuticals is recalling specific lots of Ranitidine Tablets 150 mg because the FDA detected the presence of the NDMA impurity.
Sanofi-Aventis U.S. LLC is recalling Regular Strength Zantac 150 mg tablets nationwide because an NDMA impurity was detected. This action addresses current good manufacturing practice (CGMP) deviations.
QuVa Pharma is recalling specific lots of fentanyl and ropivacaine infusions due to the potential presence of glass particulate matter.
QuVa Pharma is recalling specific lots of fentanyl and ropivacaine injection bags due to the presence of glass particulate matter.
Sanofi-Aventis U.S. LLC is recalling Regular Strength Zantac 150 mg because the FDA detected the NDMA impurity in the product.
Sanofi-Aventis U.S. LLC is recalling Regular Strength Zantac 75 mg tablets nationwide because NDMA impurity was detected. This action addresses CGMP deviations.
Sanofi-Aventis U.S. LLC is recalling Maximum Strength Zantac 150 mg tablets nationwide because an NDMA impurity was detected in the product.
QuVa Pharma is recalling fentanyl and bupivacaine injection bags due to the presence of particulate matter, specifically potential glass particles.
QuVa Pharma is recalling specific lots of fentanyl infusion solutions due to the potential presence of glass particulate matter.
QuVa Pharma is recalling specific lots of a fentanyl and bupivacaine infusion due to the presence of glass particulates.
QuVa Pharma is recalling specific lots of fentanyl and bupivacaine infusions due to the potential presence of glass particulate matter.
QuVa Pharma is recalling specific lots of fentanyl and ropivacaine injection bags due to the presence of particulate matter, including potential glass particles.
QuVa Pharma is recalling fentanyl 50 mcg/mL syringes because of potential glass particulate matter. The recall covers multiple lots distributed nationwide.
QuVa Pharma is recalling fentanyl 100 mcg/2 mL injections because of potential glass particulate matter. The recall covers specific lots distributed nationwide.
QuVa Pharma is recalling fentanyl and bupivacaine IV bags due to the presence of particulate matter, specifically potential glass particles.
QuVa Pharma is recalling fentanyl 550 mcg/55 mL syringes due to the presence of glass particulate matter.
Sanofi-Aventis U.S. LLC is recalling Regular Strength Zantac 75 mg tablets nationwide because NDMA impurity was detected in the product.
QuVa Pharma is recalling specific lots of fentanyl and ropivacaine infusions due to the potential presence of glass particulate matter.
QuVa Pharma is recalling specific lots of fentanyl and ropivacaine injection bags due to the presence of glass particulates.
QuVa Pharma is recalling specific lots of fentanyl infusion bags due to the presence of glass particulate matter.
Sanofi-Aventis U.S. LLC is recalling Regular Strength Zantac 75 mg tablets because the FDA detected the NDMA impurity in the product.